COMPANY:

BostonGene

"BostonGene...today announced a collaboration with the SWOG Cancer Research Network, a global cancer research community that designs and conducts publicly funded clinical trials, on a new multicohort study titled "S2409, PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)." This study, which is supported by the National Cancer Institute (NCI), part of the National Institutes of Health, aims to redefine the standard of care for patients with ES-SCLC by employing biomarker-driven personalized treatment strategies."

"BostonGene...today announced that its poster at the 2025 American Society of Clinical Oncology (ASCO) annual meeting has received the GRASP Advocate Choice Award. The poster, titled “Macroscale Genomic Alterations in Histomolecular Invasive Lobular Carcinoma Compared to Other Breast Cancer Subtypes,” was presented by Jason Mouabbi, MD, of The University of Texas MD Anderson Cancer Center, on June 2, 2025."

"BostonGene to Present Four Abstracts Showcasing Its Integrated Multiomic Platform Leveraging AI for Comprehensive Molecular and Immune Profiling to Inform Precision Oncology, Optimize Biomarker-Driven Trials, Accelerate Drug Development and Improve Patient Outcomes."

P=NA | N=NA | "The event, held from March 22-27 at the Boston Convention and Exhibition Center in Boston, MA....A recent pilot study uncovered associations between bacterial profiles, the tumor microenvironment (TME), and histology in metastatic castration-resistance prostate cancer (mCRPC). Using BostonGene’s machine learning-based tools, RNA sequencing data were analyzed to characterize each sample’s microbiota and TME. Distinct bacterial patterns were present across prostate cancer subtypes and TME classifications, with strong correlations observed among the microbiomes of metastatic sites."

"BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025) from March 6–8, 2025, in Kobe, Japan. This premier conference is dedicated to advancing precision oncology and fostering collaboration among global oncology experts...Unraveling sarcomatoid features in clear cell renal cell carcinoma with RNA-seq: This presentation will showcasethe value of predictive modeling in developing targeted therapy to treat clear cell renal carcinoma, emphasizing BostonGene’s Tumor Portrait^TM test in identifying unique and targetable clinical characteristics in cancer. "

"BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced a collaboration with BeiGene Ltd., a global oncology company that intends to change its name to BeOne Medicines Ltd. The collaboration centers on identifying tumor-based biomarkers associated with response and resistance in Mantle Cell Lymphoma (MCL)."

"BostonGene…announce its contributions to a white paper with Friends of Cancer Research entitled “Innovative Validation and Regulatory Processes for Companion Diagnostic Tests for Rare Biomarkers or Indications.” The paper highlights key considerations and strategic recommendations to improve the development of companion diagnostic tests for rare biomarkers and conditions to enhance patient outcomes."

"BostonGene…announced its participation in the Friends of Cancer Research (Friends) meeting, Advancing the Future of Diagnostics and Regulatory Innovations. The event, which aims to drive innovation in diagnostics and regulatory policy, will be held on February 4 at the Ritz Carlton in Washington, DC. The meeting will focus on advancing diagnostics and regulatory policy, with sessions addressing evidence generation for cutting-edge technologies like digital pathology and AI, strategies for developing tests for rare biomarkers and future regulatory considerations. New findings from the Digital PATH Project will be presented, which assessed variability in digital pathology platforms using a shared dataset. Key thought leaders will discuss how these innovations can drive precision medicine and improve patient outcomes."

"BostonGene...and Georgetown University’s Lombardi Comprehensive Cancer Center today announced a collaboration to explore the effectiveness of immune system profiling to monitor patients with gastrointestinal (GI) cancers receiving combinations of immunotherapy and anti-VEGF inhibitors in the microscopic residual disease (MRD) setting....This multi-institution feasibility study aims to identify high-risk patients with GI cancers who have completed standard of care curative-intent therapies but have MRD in the surveillance setting, defined by detectable ctDNA but no evidence of radiographic relapse. These high-risk patients are then treated with combination of atezolizumab (immune checkpoint blockade) and bevacizumab (anti-VEGF therapy) while assessing ctDNA serially for MRD clearance. The study aims to obtain pilot data on ctDNA as a new tool to detect early signals of therapeutic efficacy within months of starting treatment."

"BostonGene...today announced that four abstracts have been accepted for presentation at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19 - 23 at the Vancouver Convention Centre in Vancouver, British Columbia, Canada."

"BostonGene...announced the Company will present six posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting taking place November 6-10, 2024 at the George R. Brown Convention Center in Houston, Texas. The research, conducted in collaboration with leading cancer centers, showcases the impact of BostonGene’s technology in advancing cancer treatment strategies, from deep molecular insights to predictive biomarkers."

"BostonGene...announced its participation in the Advancing Precision Medicine (APM) Annual Conference 2024, taking place November 1-2, 2024, at the Pennsylvania Convention Center in Philadelphia...will participate in a panel discussion titled 'Diagnosis to Treatment – A Case Study in Non-Small Cell Lung Cancer.'"